GNPX - Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

• Genprex ( NASDAQ: GNPX ) stock rose ~13% on Aug. 15 after the company said that the Safety Review Committee (SRC) approved continuation of a phase 1/2 trial of Reqorsa in combination with AstraZeneca's Tagrisso (osimertinib) to treat patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso.
• The SRC decision followed a review of the first group of patients in the phase 1 portion of the phase 1/2 study called Acclaim-1.
• "The SRC approval to advance Acclaim-1 to the higher dose in the second cohort of patients is an important milestone that further supports REQORSA's safety profile and brings us one step closer to bringing this potentially ground-breaking gene therapy approach to treating NSCLC to the patients who need it most," said Genprex Chief Medical Officer Mark Berger.
• The trial includes up to three sequential dose escalation groups, the company said in an Aug. 15 press release.

For further details see: